Ionis launches an early-stage tau drug study for Alzheimer’s, picking up $10M from Biogen
After amyloid beta, the second big target in Alzheimer’s disease centers on toxic accumulations of tau, possibly working hand-in-hand with a-beta to fry people’s memories. And today Ionis $IONS says that it’s picking up a $10 million milestone from its partners at Biogen to begin an early-stage study that will set out to try and determine if its antisense tech can make a difference in disease progression.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.